Risk factors and stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy

Barry J Maron, Franco Cecchi, William J McKenna

Hypertrophic cardiomyopathy (HCM) is a primary cardiac disease characterised by a diverse clinical expression in which premature sudden unexpected death has been regarded as a critical feature of its natural history. However, it is also apparent that not all patients within the disease spectrum are at equal risk of premature death, and indeed in some individuals the disease seems to convey little or no risk.

Consequently, intense investigative interest and substantial energy have been directed toward the identification of "risk factors"—that is, those features of the disease that are perceived to predispose specific patients with HCM to sudden death or cardiac arrest. Nevertheless, despite these exploratory studies in risk stratification, there are few comprehensive and prospectively obtained long-term data analysed in a multivariate fashion. Though knowledge is rapidly evolving and workable approaches are beginning to emerge, the definition of precise approaches for most patients and clinical situations remains incomplete. Indeed, because such controversy persists regarding the definition of risk it seems justified and timely to review the available data to summarise what is known about the risk of sudden death in HCM. We hope to show that prospective trials are needed and to evolve a practical approach and workable guidelines to aid the development of diagnostic and therapeutic strategies.

Factors influencing prevalence of sudden death

Published reports indicate that premature death in patients with HCM is most often sudden and unexpected. (Sudden death is defined as unexpected, non-traumatic death occurring instantaneously or within one hour after the onset of acute symptoms or signs of cardiac dysfunction.) Reported annual mortality rates range from about 1% to 6%,. Several factors seem to be responsible for this wide range, which is found even among comparable referral centres. First, the demographic characteristics of various study groups with HCM may differ substantially. For example, annual mortality reported in studies from the 1970s is still frequently cited. These studies, however, predated echocardiography and more widespread identification of the disease (particularly the non-obstructive form). Subsequent widespread application of echocardiography dramatically altered the composition of the population of patients with HCM. Furthermore, the diagnostic criteria for HCM have evolved and have been clarified and now there is greater appreciation of the true frequency of the non-obstructive form of HCM.

Another contributing variable is the intrinsic heterogeneity and diversity of the disease's genetic and phenotypic expression, haemodynamic state, and clinical course.

Furthermore, various subgroups of patients may show different relative risks. For example, mortality was reported to be highest in children and may also differ in symptom free untreated patients and those treated in various ways.

Limitations in ascertaining risk

Several factors have limited the ability of investigators to stratify the risk of sudden cardiac death in individual patients with HCM. These include the heterogeneity of phenotypic expression which made it exceedingly difficult to establish principles of risk stratification that apply to all or most subgroups. Also, HCM is uncommon, occurring in about 0.2% of the general population, so few centres can easily assemble a patient population large enough to define risk factors for a subgroup or minority of these patients.

Consequently, certain inherent biases in patient selection and referral patterns for HCM have become important determinants of the apparent risk for sudden death. Distribution of patients among medical centres has been particularly skewed and most previous studies on clinical course, natural history, or risk stratification have been conducted retrospectively in a few selected tertiary referral institutions in North America and Western Europe. Patients are generally referred to such tertiary centres because they are already perceived to be at high risk owing to progressive symptoms; or because of a propensity to sudden premature death; or they are referred for investigational drug treatment, electrophysiological study, surgical intervention, or specialised instrumentation and device implantation. Such referral institutions may also become immersed in the detailed analysis of selected high risk pedigrees from which additional patients with unfavorable prognosis are introduced in disproportionate numbers into the overall cohort. In addition, because HCM is a complex disease, a multitude of disease variables...
Mechanisms of sudden death

Because so few sudden deaths have been fortuitously monitored, earlier descriptions of mechanisms for sudden death unavoidably have been based largely on anecdotal observations or inference. 

Therefore, various potential mechanisms that singly or in combination can lead to sudden death in patients with HCM have been studied in those who have experienced recurrent syncope, have survived cardiac arrest, or have been considered to be at increased risk of such events. These mechanisms are undoubtedly not identical in all at risk patients and may differ in youthful and older patients. Furthermore, the origins of some mechanisms appear to be primarily haemodynamic whereas others are arrhythmic. 

Proposed mechanisms of sudden death (based on such observations) include spontaneous primary ventricular tachycardia/fibrillation, paroxysmal atrial fibrillation and other supraventricular tachyarrhythmias (with or without accessory atrioventricular pathways) leading to accelerated atrioventricular conduction and ventricular fibrillation or hypotension, and conduction abnormalities involving dysfunction of the sinoatrial or atrioventricular nodes or the distal His-Purkinje system (including complete heart block). 

The haemodynamic consequences of such electrophysiological abnormalities may be exaggerated by the presence of dynamic obstruction to left ventricular outflow, by severe impairment of diastolic filling, or by the induction of myocardial ischaemia (possibly owing to reduced coronary reserve secondary to abnormalities of the intramural small vessels) and fibrosis, which can reduce the threshold for ventricular arrhythmias. Alternatively, the finding of ischaemia or outflow obstruction in patients with syncope or aborted cardiac arrest, or of severe exercise hypotension despite an appropriate increase in cardiac output suggests that some patients these pathophysiological mechanisms can have a primary role in provoking sudden cardiac death. 

What determines the clinical outcome after an arrhythmic, ischaemic, or vascular triggering event? Though unproven, the working hypothesis of many investigators is that the arrhythmogenic substrate is the extent and potential risk factors have been identified (and continue to be described), further confounding risk stratification assessment. Previous efforts at establishing relative risk in patients with HCM should be viewed in the context of these limitations, particularly the utilisation of patients at tertiary centres who were already largely preselected because they were perceived to be at increased risk even before they were referred.

Clinical profile

Sudden cardiac death in hypertrophic cardiomyopathy seems to be most common in children and young adults, aged 12–35 years (fig 1), though it may also occur in older adults, even in those who have previously been symptom free. Sudden death seems to be uncommon in the first decade of life: currently, however, there are few data on this subgroup of patients. Most patients with HCM who die suddenly have been symptom free (or have had only mild symptoms) and often their disease has not been identified clinically (fig 1). Patients with functional limitation can also die suddenly and unexpectedly; however, we regard deaths that occur suddenly in patients with profound congestive heart failure (whether or not this is associated with the end stage of HCM) to be outside the context of this discussion. Most patients (about 60%) experience sudden death while they are inactive or only mildly active. But about 40% die during or just after vigorous physical activities, including competitive sports (fig 1); indeed, HCM seems to be the most common cause of sudden death in young competitive athletes. Also, although operation (usually septal myotomy/myectomy) relieves symptoms in most patients, such individuals can die suddenly many years after successful surgical relief of outflow obstruction.
severity of myocardial disarray and that this is an important determinant of electrical stability and survival. Identification of the arrhythmogenic substrate (or measurements that reflect it) remains a major goal in the characterisation of patients with HCM.

Finally, as in ischaemic heart disease, sudden death in HCM is common in the morning hours (7am-1pm). The significance of this circadian pattern is uncertain, although it does suggest a possible role for the temporarily related physiological changes (possibly involving arrhythmias and the electrical vulnerability of the myocardium).

**ARRHYTHMIAS**

Various arrhythmias are common in patients with HCM. In many instances of sudden death the circumstances suggest a primary ventricular arrhythmia as the cause, and a close relation between ventricular arrhythmias and sudden death has been inferred. Therefore, understandably, considerable effort has focused on the potential significance of ventricular arrhythmias identified on the ambulatory (Holter) electrocardiogram in stratifying risk in this disease. Two tertiary referral centres independently studied a total of 169 largely medically treated and predominantly adult patients with HCM and linked short runs of asymptomatic ventricular tachycardia on ambulatory electrocardiogram (usually 3 to 10 consecutive beats) with an enhanced risk of sudden cardiac death.

In these studies ventricular tachycardia conferred an 8% per year risk of sudden death (over the subsequent 3 years) as compared with less than 1% per year in the absence of ventricular tachycardia (fig 2), with a high negative and low positive predictive accuracy (96% and 26%, respectively). The low positive predictive accuracy indicates significant heterogeneity of risk within the subset of patients with non-sustained ventricular tachycardia. It has also been suggested that non-sustained ventricular tachycardia may not have identical significance as a marker of sudden cardiac death in "stable low-risk" and unselected groups of patients with HCM compared with those into which higher risk patients have been preferentially referred.

Despite this limitation, the finding of ventricular tachycardia on Holter monitoring remains a useful and practical non-invasive screening test for risk of sudden cardiac death in adult patients with HCM. The presence of ventricular tachycardia places the patient in a high risk group for which further risk evaluation or empirical treatment to prevent sudden death should be considered. In those patients in whom non-sustained tachycardia is a risk factor, it may primarily reflect the arrhythmogenic substrate or more specifically that as a trigger mechanism for sudden cardiac death.

**Risk factors for sudden death**

Tables 1 and 2 summarise the large number of disease variables that have at one time or another been regarded as risk factors for patients with HCM. They underline the inherent complexities of risk factor stratification strategies in this disease.

**CLINICAL FEATURES**

Some patients with HCM die young, but the risk declines with increasing age. During pregnancy, there is evidence from unusually frequent occurrence (or "clusters") of sudden death in some pedigrees that such a "malignant" family history may itself be a risk factor for those surviving and for affected relatives in the same pedigree. Indeed, this view is consistent with the recent observation that particular genetic defects involving contractile proteins, troponin T, a troponymosin, and various missense mutations in the β myosin heavy chain gene may be associated with favourable or unfavourable clinical course in certain families. Among the particular cardiac symptoms incurred by patients with HCM, only syncope in children and adolescents has been shown to be associated with subsequent sudden death; however, a likely mechanism for syncope can be identified in only <20% of patients.

![Figure 2](image_url) Comparisons of prevalence of sudden death (or cardiac arrest) in 169 HCM patients with or without ventricular tachycardia (VT) on ambulatory (Holter) electrocardiography. Shown separately for 83 patients studied in the United States (Bethesda, MD) with 24 h Holter recording and for 86 patients studied in the United Kingdom (London) with 72 h Holter.

**Table 1** Probable risk factors associated with sudden cardiac death in hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Youth</td>
<td>&quot;Malignant&quot; family history of sudden death</td>
</tr>
<tr>
<td>Abnormalities associated with increased prevalence of sudden death</td>
<td></td>
</tr>
<tr>
<td>Aborted sudden cardiac death</td>
<td></td>
</tr>
<tr>
<td>Sustained ventricular or supraventricular tachyarrhythmias</td>
<td></td>
</tr>
<tr>
<td>Recurrent syncope in the young</td>
<td></td>
</tr>
<tr>
<td>Non-sustained ventricular tachycardia (Holter monitoring)</td>
<td></td>
</tr>
<tr>
<td>Bradycardiac (occlut conduction disease)</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2** Potential risk factors for sudden cardiac death in hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased left ventricular thickness and mass</td>
<td></td>
</tr>
<tr>
<td>Tachycardia-induced myocardial ischaemia</td>
<td></td>
</tr>
<tr>
<td>Pronounced dynamic left ventricular outflow tract obstruction</td>
<td></td>
</tr>
<tr>
<td>Dispersion and inhomogeneity of intraventricular conduction</td>
<td></td>
</tr>
<tr>
<td>Exercise-induced hypotension</td>
<td></td>
</tr>
<tr>
<td>Pronounced physical exertion</td>
<td></td>
</tr>
<tr>
<td>Morning hours of the day</td>
<td></td>
</tr>
</tbody>
</table>

Br Heart J: first published as 10.1136/hrt.72.6_Suppl.S13 on 1 December 1994. Downloaded from http://heart.bmj.com/ on June 5, 2021 by guest. Protected by copyright.
association between considerable and diffuse hypertrophy and subsequent sudden cardiac death and also with non-sustained ventricular tachycardia on the ambulatory electrocardiogram. In one such study, considerably increased left ventricular wall thickness and diffuse distribution of hypertrophy was eight times more common in patients with HCM and sudden cardiac death than in surviving controls with this disease. On the other hand, relatively mild degrees of hypertrophy are not without risk of sudden death and even occasional patients, apparently within the disease spectrum of HCM but without left ventricular wall thickening have died.

Though these relations between the extent of hypertrophy and the predisposition to sudden death may be statistically significant they also show substantial overlap. Also, it is often difficult to relate the magnitude of left ventricular hypertrophy to the clinical course because wall thickness measurements can change with time and age. Consequently, at present we cannot use echocardiography to predict reliably which patients with HCM are at the greatest risk of sudden death.

**HAEMODYNAMICS**

Many patients with HCM show evidence of haemodynamic instability during exercise with systemic hypotension owing to a fall in systemic vascular resistance (and in the presence of increasing cardiac index). The ultimate clinical significance of this finding is unresolved, although the findings of haemodynamic instability, youth, and a family history of sudden death have been regarded as a constellation that may predispose the patient to sudden death.

In contrast, several other haemodynamic variables do not seem to be predictable determinants of the risk of sudden death in HCM. For example, patients with outflow obstruction and those without may both experience sudden death and no relation between the magnitude of outflow gradient and likelihood of sudden death has ever been established. Nevertheless, it is still possible that in many patients considerable left ventricular outflow tract gradients and raised intraventricular systolic (and diastolic) pressures, through several pathophysiological mechanisms, predispose patients to potentially lethal arrhythmia and sudden cardiac death. Furthermore, indices of systolic or diastolic dysfunction (assessed by radionuclide or contrast angiography or echocardiography) have not been linked convincingly with sudden cardiac death and have not contributed measurably to risk stratification.

**MORPHOLOGY**

Initial necropsy descriptions of patients who died suddenly of HCM consistently showed a striking expression of the disease with a substantial increase in left ventricular wall thickness and mass. Though the pattern and extent of left ventricular wall thickening in HCM is diverse, echocardiographic analyses of selected patients have shown some statistical

---

**Figure 3** Proposed benefit of amiodarone in patients with HCM. Cumulative survival rate was greater in 21 mildly symptomatic patients with HCM and non-sustained ventricular tachycardia (VT) (on ambulatory ECG monitoring) treated with amiodarone than in a similar group of 24 patients with HCM and non-sustained ventricular tachycardia treated with conventional antiarrhythmic medications. 123 patients with HCM without ventricular tachycardia are shown for comparison (adapted from McKenna et al; reproduced with permission of the British Heart Journal).
Risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy


